RGNX: REGENXBIO Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 377.38
Enterprise Value ($M) 379.54
Book Value ($M) 259.65
Book Value / Share 5.18
Price / Book 1.45
NCAV ($M) 71.66
NCAV / Share 1.43
Price / NCAV 5.27

Profitability (mra)
Return on Invested Capital (ROIC) -0.57
Return on Assets (ROA) -0.36
Return on Equity (ROE) -0.58

Liquidity (mrq)
Quick Ratio 2.69
Current Ratio 2.69

Balance Sheet (mrq) ($M)
Current Assets 278.00
Assets 465.99
Liabilities 206.34
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 83.33
Operating Income -231.25
Net Income -227.10
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -173.12
Cash from Investing 103.45
Cash from Financing 92.68

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
04-24 13G/A BlackRock, Inc. 7.30 -32.70
02-12 13G/A Jpmorgan Chase & Co 7.40 49.41
02-05 13G State Street Corp 4.40 -16.93
01-31 13G/A Vanguard Group Inc 6.02 -31.66
11-14 13G/A Redmile Group, LLC 9.90 31.42

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 118,915 792,958 15.00
2025-05-08 510,787 2,187,227 23.35
2025-05-07 213,528 1,783,335 11.97
2025-05-06 361,621 1,989,004 18.18
2025-05-05 120,055 680,260 17.65

(click for more detail)

Similar Companies
REGN – Regeneron Pharmaceuticals, Inc. REPL – Replimune Group, Inc.
RGEN – Repligen Corporation RIGL – Rigel Pharmaceuticals, Inc.
RLMD – Relmada Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io